The impact of COVID-19 on pregnancy and therapeutic drug development.

Content Provider	Europe PMC
Author	Abbas‐Hanif, Allyah Rezai, Homira Ahmed, Syed Faraz Ahmed, Asif
Abstract	Emerging data show that pregnant women with COVID‐19 are at significantly higher risk of severe outcomes compared with non‐pregnant women of similar age. This review discusses the invaluable insight revealed from vaccine clinical trials in women who were vaccinated and inadvertently became pregnant during the trial period. It further explores a number of clinical avenues in their management and proposes a drug development strategy in line with clinical trials for vaccines and drug treatments for the drug development community. Little is known of the long‐term effects of COVID‐19 on the mother and the baby. Our hypothesis that COVID‐19 predisposes pregnant women to pre‐eclampsia or hypertensive disorders during pregnancy is supported by a clinical study, and this may also adversely impact a woman's cardiovascular disease risk later in life. It may also increase a woman's risk of pre‐eclampsia in subsequent pregnancy. This is an ever‐evolving landscape, and early knowledge for healthcare providers and drug innovators is offered to ensure benefits outweigh the risks. COVID‐19 mRNA vaccines appear to generate robust humoral immunity in pregnant and lactating women. This novel approach to vaccination also offers new ways to therapeutically tackle disorders of many unmet medical needs.LINKED ARTICLESThis article is part of a themed issue on The second wave: are we any closer to efficacious pharmacotherapy for COVID 19? (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.10/issuetoc
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8239854&blobtype=pdf
Page Count	13
ISSN	00071188
Journal	British Journal of Pharmacology [Br J Pharmacol]
Volume Number	179
DOI	10.1111/bph.15582
PubMed Central reference number	PMC8239854
Issue Number	10
PubMed reference number	34085281
e-ISSN	14765381
Language	English
Publisher	John Wiley and Sons Inc.
Publisher Date	2021-07-06
Publisher Place	Hoboken
Access Restriction	Open
Rights License	This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Subject Keyword	cardiovascular diseases clinical trials COVID‐19 drug development pre‐eclampsia pregnancy vaccines
Content Type	Text
Resource Type	Article
Subject	Pharmacology